By Daniel B. Drachman, MD, FAAN - Two clinical trials of treatment of myasthenia gravis (MG) with mycophenolate mofetil (MMF) in Neurology® report lack of efficacy. Unfortunately, both trial protocols were flawed, with relatively short durations of treatment, unexpectedly good responses to concomitant steroid treatment, and problems in the efficacy measure. However, excellent results, and a favorable profile of side effects, observed in numerous myasthenic patients treated by experienced clinicians require that these published trials be considered in context. In the meantime, MMF must remain available for treatment of MG. Future trial designs should consider prolonged time course, interactions of other immunosuppressive agents, and a more appropriate outcome method.Science at the Annual Meeting
The AAN Annual Meeting brings together more than 10,000 neuroscience professionals for one of the world's largest neurology gatherings. It has long been a leading showcase for the latest developments in scientific research, and the place to honor peers at the forefront of the work.
View 2008 Scientific Abstracts
Science Press Releases from the AAN
Late-Breaking Science
The deadline for submitting a late-breaking science abstract for the 60th Annual Meeting has passed. Applicants will be notified in early March of their status.
Major Lectures From 2007
| Amyotropic Lateral Sclerosis: From Mutations to Mechanisms and Medicines
Robert H. Brown, Jr., MD, DPhil - Tuesday, May 1, 2007 10:45 - 11:15 a.m. |
| Neural Interfaces to Restore Function
John P. Donoghue, PhD - Tuesday, May 1, 2007 5:15 - 5:30 p.m. |
| Progranulin Mutations in FTDP-17: Genetic and Clinical Implications
Michael Hutton, PhD - Tuesday, May 1, 2007 5:30 - 5:45 p.m. |
| Waking up to Sleep: Implications for Neurology Clifford B. Saper, MD, PhD, FAAN - Tuesday, May 1, 2007 5:45 - 6:00 p.m. |
| Inhibition of B Cell Functions: Implications for Neurology
Marinos C. Dalakas, MD, FAAN - Tuesday, May 1, 2007 6:00 - 6:15 p.m. |
| Genetic Correlates of Brain Aging on MRI and Cognitive Test Measures: Genome Wide Associated Analysis in the Framingham Heart Study
Sudha Seshadri, MD - Wednesday, May 2, 2007 9:05 - 9:30 a.m. |
| The Neurochemical Aftermath of Amateur Boxing
Max Albert Hietala, MD, PhD - Wednesday, May 2, 2007 9:30 - 9:55 a.m. |
| Secondary Analysis of Hemorrhagic Stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Larry B. Goldstein, MD, FAAN - Wednesday, May 2, 2007 9:05 - 9:30 a.m. |
| Sodium Channels as Targets for Pain Management: Lessons from Inherited Pain Syndromes
C. Geoffrey Woods, MD - Wednesday, May 2, 2007 10:30 - 10:50 a.m. |
| Idebenone Treatment for Friedreich's Ataxia Kenneth H. Fischbeck, MD, FAAN - Wednesday, May 2, 2007 10:50 - 11:10 a.m. |
| How Should We Treat the Patient with Persistent Painful Lumbosacral Radiculopathy?
J.D. Bartleson, MD, FAAN - Wednesday, May 2, 2007 11:10 - 11:30 a.m. |
| Parkinson's Disease: Beyond the Decade of the Brain Anthony E. Lang, MD, FAAN - Thursday, May 3, 2007 9:05 - 9:30 a.m. |
| Channels, Genes, Hormones, and Migrane
Michael A. Moskowitz, MD, FAAN - Thursday, May 3, 2007 9:30 - 10:00 a.m. |
| The Alzheimer-Frontotemporal Spectrum: A Molecular Approach
Christine Van Broeckhoven, PhD, DSc - Thursday, May 3, 2007 10:00 - 10:30 a.m. |
| Autonomic Neuropathy: Progress in Pathogenesis and Treatment
Phillip A. Low, MBBS, MD, FRACP, FRCP (Hon) - Thursday, May 3, 2007 10:30 - 11:00 a.m. |
